XNAS · Healthcare · Biotechnology
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | 0.33 | 0.43 | +30.30% | $127.4M | ✅ Beat | +0.40% | +1.64% | — |
| 2026-03-05 | Q4 2025 | 0.83 | 0.61 | -26.51% | $128.6M | ❌ Miss | +6.18% | +1.59% | +11.90% |
| 2025-11-12 |
| Q3 2025 |
| 0.57 |
| 0.57 |
| +0.00% |
| $104.3M |
| ➖ Inline |
| — |
| — |
| — |
| 2025-03-25 | Q4 2024 | 0.14 | 0.22 | +57.14% | $31.2M | ✅ Beat | -2.45% | -17.30% | +24.66% |
| 2024-08-14 | Q2 2024 | -0.25 | -0.25 | +0.00% | $806,119 | ➖ Inline | -2.54% | +1.83% | +41.26% |
| 2024-05-09 | Q1 2024 | -0.28 | -0.25 | +10.71% | $0 | ✅ Beat | -4.44% | -3.88% | -5.92% |
| 2024-03-12 | Q4 2023 | -0.20 | -0.26 | -30.00% | $0 | ❌ Miss | — | — | — |
| 2023-11-14 | Q3 2023 | -0.21 | -0.17 | +19.05% | $0 | ✅ Beat | +6.39% | +15.65% | +10.22% |
Showing last 8 quarters.